New hope for hard-to-treat lymphoma: experimental drug targets cancer cells directly
NCT ID NCT07332507
First seen Jan 12, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This early-stage trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has come back or not improved after prior therapy. The drug works by attaching to both cancer cells and immune cells, helping the immune system attack the lymphoma. The study aims to find the safest dose and check if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PLASMABLASTIC LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.